Review of Post-Marketing Safety Data on Tapentadol, a Centrally Acting Analgesic.

ABSTRACT: INTRODUCTION:Tapentadol is a centrally acting analgesic that has been available for the management of acute and chronic pain in routine clinical practice since 2009. METHODS:This is the first integrated descriptive analysis of post-marketing safety data following the use of tapentadol in a broad range of pain conditions relating to the topics overall safety, dose administration above approved dosages, administration during pregnancy, serotonin syndrome, respiratory depression, and convulsion. The data analyzed pertain to spontaneous reports from healthcare and non-healthcare professionals and were put in the context of safety information known from interventional and non-interventional trials. RESULTS:The first years of routine clinical practice experience with tapentadol have confirmed th

SUBMITTER: Stollenwerk A 

PROVIDER: S-EPMC5778188 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature